A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With MabThera vs no Treatment, After Induction With MabThera, Cladribine and Cyclophosphamide on Progression-Free Survival in Previously Untreated Patients With Progressive B-CLL. The Trial Conducted With PALG Sites.

Trial Profile

A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With MabThera vs no Treatment, After Induction With MabThera, Cladribine and Cyclophosphamide on Progression-Free Survival in Previously Untreated Patients With Progressive B-CLL. The Trial Conducted With PALG Sites.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Rituximab (Primary) ; Cladribine; Cyclophosphamide
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 11 May 2015 Planned End Date changed from 1 May 2017 to 1 Dec 2016, according to to ClinicalTrials.gov record.
    • 11 May 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top